JP6757121B2 - シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 - Google Patents

シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 Download PDF

Info

Publication number
JP6757121B2
JP6757121B2 JP2014534785A JP2014534785A JP6757121B2 JP 6757121 B2 JP6757121 B2 JP 6757121B2 JP 2014534785 A JP2014534785 A JP 2014534785A JP 2014534785 A JP2014534785 A JP 2014534785A JP 6757121 B2 JP6757121 B2 JP 6757121B2
Authority
JP
Japan
Prior art keywords
adenovirus
seq
acid sequence
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014534785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530606A (ja
Inventor
イー． ブラフ、ダグラス
イー． ブラフ、ダグラス
ジー．ディー． ガル、ジェイソン
ジー．ディー． ガル、ジェイソン
マクヴェイ、ダンカン
Original Assignee
ジェンヴェック エルエルシー
ジェンヴェック エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンヴェック エルエルシー, ジェンヴェック エルエルシー filed Critical ジェンヴェック エルエルシー
Publication of JP2014530606A publication Critical patent/JP2014530606A/ja
Priority to JP2018137237A priority Critical patent/JP6970647B2/ja
Application granted granted Critical
Publication of JP6757121B2 publication Critical patent/JP6757121B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014534785A 2011-10-05 2012-10-05 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法 Active JP6757121B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018137237A JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543661P 2011-10-05 2011-10-05
US61/543,661 2011-10-05
PCT/US2012/059006 WO2013052832A2 (en) 2011-10-05 2012-10-05 Adenoviral vectors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018137237A Division JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法

Publications (2)

Publication Number Publication Date
JP2014530606A JP2014530606A (ja) 2014-11-20
JP6757121B2 true JP6757121B2 (ja) 2020-09-16

Family

ID=47045181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014534785A Active JP6757121B2 (ja) 2011-10-05 2012-10-05 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2019169775A Active JP7394285B2 (ja) 2011-10-05 2019-09-18 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018137237A Active JP6970647B2 (ja) 2011-10-05 2018-07-20 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP2019169775A Active JP7394285B2 (ja) 2011-10-05 2019-09-18 シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法

Country Status (7)

Country Link
US (4) US9617560B2 (enrdf_load_stackoverflow)
EP (1) EP2764014B1 (enrdf_load_stackoverflow)
JP (3) JP6757121B2 (enrdf_load_stackoverflow)
CN (2) CN107574154A (enrdf_load_stackoverflow)
BR (1) BR112014008284A2 (enrdf_load_stackoverflow)
CA (1) CA2851251C (enrdf_load_stackoverflow)
WO (1) WO2013052832A2 (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
JP6757121B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP6757119B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
US9676824B2 (en) * 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
JP7535852B2 (ja) 2016-08-23 2024-08-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原がインバリアント鎖（ｃｄ７４）の小断片と連結された融合ペプチド
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
MX2019006722A (es) 2016-12-09 2019-08-22 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
US11649467B2 (en) 2017-07-21 2023-05-16 Glaxosmithkline Biologicals Sa Chikungunya virus antigen constructs
CN111295391B (zh) * 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
KR20200128703A (ko) 2018-03-06 2020-11-16 프레시전 인코포레이티드 B형 간염 백신 및 이의 용도
WO2019173465A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP7640538B2 (ja) 2019-10-08 2025-03-05 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ATE278794T1 (de) 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
WO1997026911A1 (en) 1996-01-29 1997-07-31 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
EP1425045A4 (en) 2001-09-13 2004-11-10 Genvec Inc ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ，インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
DE102005006388A1 (de) * 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
WO2010051367A1 (en) * 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
CA2749325C (en) 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2011014794A1 (en) 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
JP5980117B2 (ja) 2009-11-09 2016-08-31 ジェンヴェック，インコーポレーテッド サルアデノウイルスベクターの増殖方法
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2013052859A2 (en) * 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
US9629906B2 (en) * 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
JP6757121B2 (ja) * 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP6757119B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
EP2809346A1 (en) * 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine

Also Published As

Publication number Publication date
JP7394285B2 (ja) 2023-12-08
US10059962B2 (en) 2018-08-28
CN107574154A (zh) 2018-01-12
CA2851251C (en) 2023-09-12
JP2020022459A (ja) 2020-02-13
US20190055579A1 (en) 2019-02-21
JP6970647B2 (ja) 2021-11-24
EP2764014A2 (en) 2014-08-13
CA2851251A1 (en) 2013-04-11
CN103987726B (zh) 2017-10-03
US20140314717A1 (en) 2014-10-23
JP2018196383A (ja) 2018-12-13
US10787682B2 (en) 2020-09-29
US20170211097A1 (en) 2017-07-27
EP2764014B1 (en) 2022-02-09
WO2013052832A3 (en) 2013-06-06
US11359214B2 (en) 2022-06-14
WO2013052832A2 (en) 2013-04-11
US9617560B2 (en) 2017-04-11
BR112014008284A2 (pt) 2020-10-27
CN103987726A (zh) 2014-08-13
US20210040502A1 (en) 2021-02-11
JP2014530606A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
JP6970060B2 (ja) アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
JP6970647B2 (ja) シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
JP6970059B2 (ja) アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140626

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180320

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20180720

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20180828

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20180828

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190409

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200331

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200630

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20200804

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200828

R150 Certificate of patent or registration of utility model

Ref document number: 6757121

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250